ATYR
aTyr Pharma, Inc.0.7326
-0.0008-0.11%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
71.79MP/E (TTM)
-Basic EPS (TTM)
-0.83Dividend Yield
0%Recent Filings
8-K
Nasdaq bid price deficiency
aTyr Pharma received a Nasdaq deficiency notice on December 4, 2025, for its common stock closing below $1.00 per share over 30 consecutive business days, violating Listing Rule 5550(a)(2). The stock remains listed, with 180 days until June 2, 2026, to sustain $1.00 closes for 10 straight business days. No immediate delisting. Company will monitor prices and explore fixes like a reverse split.
10-Q
Q3 FY2025 results
aTyr Pharma posted Q3 revenue of $0.2M from Kyorin drug sales, up from zero y/y, yet ramped R&D to $22.1M (up 49% y/y) on efzofitimod manufacturing for potential BLA while wrapping EFZO-FIT. Operating loss hit $26.7M (vs $18.1M y/y), net loss $25.7M or $(0.26)/share on 97M shares, matching diluted count amid net loss position. Cash plus investments stood at $92.9M after $66.4M ATM raise, funding ops for 12+ months; op cash burn eased to $(49.8M) YTD (derived, down 11% y/y). No debt beyond leases. Cash burn funds the runway.
8-K
Phase 3 misses primary, gains QoL
aTyr Pharma reported Q3 2025 results, with Phase 3 EFZO-FIT™ missing its primary corticosteroid reduction endpoint in pulmonary sarcoidosis yet showing efzofitimod benefits in quality of life, fatigue, and steroid withdrawal at 5.0 mg/kg. Cash stood at $92.9 million. FDA meeting set for Q1 2026. Phase 2 SSc-ILD enrollment finishes H1 2026.
8-K
Phase 3 misses primary endpoint
aTyr Pharma announced topline results from its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis on September 15, 2025, missing the primary endpoint of reducing mean daily oral corticosteroid dose to 2.79 mg versus 3.52 mg for placebo (p=0.3313). Yet, the 5.0 mg/kg dose showed clinical improvement in KSQ-Lung scores (p=0.0479) and higher complete steroid withdrawal with lung function improvement (29.5% vs 14.4%, p=0.0199). The drug proved well-tolerated. aTyr plans FDA engagement to chart next steps, while risks hinge on regulatory feedback.
8-K
Phase 3 efzofitimod study completes
aTyr Pharma wrapped up the last patient visit in its Phase 3 EFZO-FIT™ study of efzofitimod for pulmonary sarcoidosis, with topline results due mid-September 2025. This milestone advances the lead candidate in interstitial lung disease, while interim Phase 2 data from EFZO-CONNECT™ in scleroderma-related ILD showed stable skin scores and biomarker improvements in eight patients. Cash stood at $83.2 million as of June 30, bolstered by $30.7 million from an ATM offering. Topline data will shape efzofitimod's path forward.
ATHA
Athira Pharma, Inc.
3.88+0.03
ATXS
Astria Therapeutics, Inc.
12.87-0.05
AVIR
Atea Pharmaceuticals, Inc.
3.22+0.07
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
KRRO
Korro Bio, Inc.
8.22+0.26
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
RNTX
Rein Therapeutics, Inc.
1.35-0.13
TVRD
Tvardi Therapeutics, Inc.
4.20-0.02
TYRA
Tyra Biosciences, Inc.
22.97+0.85